Combivir

A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube
AIDS virusCombivir belongs to a class of anti-HIV drugs called Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs). For a description of the life-cycle of the AIDS virus, and the targets of each class of drugs, click here.

Combivir is marketed by ViiV Healthcare.

AIDS drugs chartOur quick-reference chart allows you to compare all the currently available anti-HIV drugs, including dosing, side effects, & dietary restrictions.
news Treatment News
Search for recent news and archived stories about Combivir.
forumsHave more questions? Then post a question or comment in our Community Forums.
Help Paying for MedsHelp Paying for Meds: Patient assistance and co-pay programs for HIV and viral hepatitis drugs.
Lessons Our Lessons: Check out our informative Lessons covering various topics to help you make treatment decisions.
Collapse All

Recommended Reading List:

Books about AIDS & HIV treatmentsFor a list of great books about living with HIV and making informed treatment decisions, along with easy links to buy them from Amazon.com, click here.

Combivir (zidovudine + lamivudine)

Pronunciation(s): COM-bih-veer; zye-DOE-vue-deen; la-MI-vue-deen



What is Combivir?
  • Combivir is an HIV medication. It is in a category of HIV medicines called nucleoside reverse transcriptase inhibitors (NRTIs). Combivir prevents HIV from altering the genetic material of healthy CD4 cells. This prevents the cells from producing new virus and decreases the amount of virus in the body.
     
  • Combivir is marketed by ViiV Healthcare. It was approved by the U.S. Food and Drug Administration (FDA) for use by people living with HIV in 1997.
     
  • Combivir is a combination of two drugs: 300mg of Retrovir (zidovudine) and 150mg of Epivir (lamivudine). Combivir should be prescribed by a healthcare provider for patients who need both of these drugs. Both of these drugs can still be purchased individually for use in combination with other HIV drugs.
     
  • Combivir must be combined with at least one other HIV drug, usually a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI).
     
  • A patient assistance program (PAP) has been established for people living with HIV who do not have private or public health insurance and are unable to afford Combivir. To learn more about the PAP for Combivir, call 877-784-4842 or refer to the program's website for more information. For those with private health insurance, a program has been established to help cover each Combivir co-payment, up to $100 every month. To learn more about this co-pay program, check out mysupportcard.com.

What is known about Combivir?
  • Combivir is taken twice daily, one tablet in the morning and one tablet in the evening, with or without food.
     
  • Combivir should not be any more or less effective than Retrovir and Epivir taken as separate pills together. However, it is considered to be a much more convenient way of taking these two anti-HIV drugs.
     
  • For HIV-positive adults beginning HIV drug therapy for the first time, Combivir is listed as an "alternative" NRTI option by the United States Department of Health and Human Services in its treatment guidelines. Tenofovir and emtricitabine, used together as Truvada or as a part of Atripla (efavirenz, tenofovir and emtricitabine), is listed as the "preferred" dual-NRTI option. For HIV-positive pregnant women, however, Combivir is listed as a "preferred" NRTI option, when combined with the protease inhibitor Kaletra (lopinavir/ritonavir). To learn more about these recommendations and options, click here.
     
  • See the "What is known about..." sections of Retrovir and Epivir for information about possible drug resistance.

What about drug interactions?
  • Combivir should not be taken at the same time as Emtriva or Truvada (containing Viread and Emtriva). This is because the Epivir in Combivir is very similar to Emtriva, and it is not believed that combining these two HIV drugs will make a regimen any more effective against the virus. Similarly, Combivir should not be taken at the same time as Retrovir, Epivir, Epzicom (containing Ziagen and Epivir) or Trizivir (containing Ziagen, Epivir and Retrovir).
     
  • See the "What about drug interactions?" sections of Retrovir and Epivir.

What about side effects?
  • Bone marrow problems, such as decreased production of red blood cells and/or white blood cells, can occur in people talking Retrovir, one of the two active drugs in Combivir. Contact your doctor immediately if you develop unusual fatigue, pale skin, sore throat, fever, or chills, which may be signs of bone marrow problems.
     
  • A rare but potentially serious side effect of Retrovir, one of the two drugs in Combivir, is myopathy (damage to the muscles, including the heart). People who use Retrovir for a long period of time, meaning several years, are at the greatest risk for myopathy. General symptoms of myopathy include weakness of limbs, usually proximal (located close to the center of the body).
     
  • Lactic acidosis, which can be fatal, and severe liver problems have been reported in people taking nucleoside reverse transcriptase inhibitors (NRTIs), including Retrovir and Epivir, the two active drugs in Combivir. Contact your doctor immediately if you experience nausea, vomiting, or unusual or unexpected stomach discomfort; weakness and tiredness; shortness of breath; weakness in the arms and legs; yellowing of the skin or eyes; or pain in the upper stomach area.
     
  • HIV drug regimens containing nucleoside reverse transcriptase inhibitors (NRTIs), including Combivir, can cause increased fat levels (cholesterol and triglycerides) in the blood, abnormal body-shape changes (lipodystrophy; including increased fat around the abdomen, breasts, and back of the neck, as well as decreased fat in the face, arms, and legs), and diabetes. These side effects of HIV drug therapy are reviewed in our lessons on Lipodystrophy, Facial Lipoatrophy, and Risks To Your Heart (Hyperlipidemia).
     
  • If you have hepatitis B and HIV and plan to stop taking Combivir, your doctor might want to frequently check your liver enzymes after stopping treatment. This is because the Epivir in Combivir is also active against the hepatitis B virus (HBV). If Epivir is stopped abruptly, it can cause liver disease to "flare" and damage the liver.
     
  • See the "What about side effects?" sections of Retrovir and Epivir for additional possible side effects.

Can pregnant women take Combivir?
  • Combivir is classified by the FDA as a pregnancy category C drug. Pregnancy category C means that animal studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. HIV-positive women who become pregnant should discuss the benefits and possible side effects of HIV treatment to help protect their babies from HIV (see our lesson called Family Planning, Pregnancy & HIV).
     
  • It is not known whether Combivir passes into breast milk and what effect they may have on a nursing baby. To prevent transmission of the virus to uninfected babies, it is recommended that HIV-positive mothers not breast-feed.

What should I tell my doctor before taking Combivir?
  • Before taking this medication, tell your doctor if you have: kidney disease; liver disease (including hepatitis B); or low blood cell counts (anemia or low white blood cells).
     
  • Tell your doctors and pharmacists about all medicines you take. This includes prescription medications, over-the-counter products, or herbal/natural remedies.

Where can I learn more about clinical trials involving Combivir?
  • If you would like to find out if you are eligible for any clinical trials that include Combivir, visit ClinicalTrials.gov, a site run by the U.S. National Institutes of Health. The site has information about all HIV-related clinical studies in the United States. For more info, you can call their toll-free number at 1-800-HIV-0440 (1-800-448-0440) or email contactus@aidsinfo.nih.gov.

Last Revised: February 07, 2011

This content is written by the POZ and AIDSmeds editorial team. For more information, please visit our "About Us" page.


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.